Ixazomib (Ninlaro), the first oral PI All were approved for use in relapsed/refractory multiple myeloma, although daratumumab was also approved for newly diagnosed disease.

New criteria make high-risk smoldering multiple myeloma treatable, opening door to future 'chronic' disease status ...